Johnson & Johnson Innovative Medicine company-sponsored congress materials which have been accepted for congress presentation at American Society of Hematology

Quality-Adjusted Survival Analysis of Neurologic Events With Ciltacabtagene Autoleucel vs Standard of Care in Patients With Lenalidomide-Refractory Multiple Myeloma Who Received 1–3 Prior Lines of Therapy: CARTITUDE-4 Trial Population

CARVYKTI_US-SR-10459

Tremfya Dossier Update- bottom

rybrevant dossier update - bottom

Imaavy Dossier Update- bottom

Lazcluze Dossier Update - bottom

CARVYKTI_US-SR-10545

Test-EL

Carvykti Dossier banner

Submit your medical inquiry

Contact J&J Medical Connect for your medical inquiries


This page was last modified on

Additional contact #{index}

janssenscience

Congress Materials

Payer

carvykti

Dark Blue

oncology

quality-adjusted-survival-analysis-of-neurologic-video

Whitelist Modal

Quality-Adjusted Survival Analysis of Neurologic Events With Ciltacabtagene Autoleucel vs Standard of Care in Patients With Lenalidomide-Refractory Multiple Myeloma Who Received 1–3 Prior Lines of Therapy: CARTITUDE-4 Trial Population

Connect with us

Connect with us

Live video

Waiting for agent...

Ready to join